6.24MMarket Cap
LossP/E TTM
Key Figures
1.600Open
1.610High
50.18KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.28%Turnover Ratio
1.600Prev. Close
1.570Low
64.00KTurnover
LossP/E Static
1.86P/B
0.00%Div Yield TTM
-196.78%ROA
41.21752wk High
0.28Volume Ratio
-18.62MNet Profit
3.92MShares
-3.9958EPS TTM
1.97Beta
-768.25%ROE
2.08052wk Low
2.50%Amplitude
100.00%Gross Margin
6.24MMarket Cap
-4.56Reward/Risk
3.56%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Imunon Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 120 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Imunon Inc Highlights
StrengthsRisks
Imunon Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
25
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Imunon Inc Info
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Ticker SymbolIMNN
CompanyImunon Inc
CEOLindborg (Stacy R)
Websitehttps://imunon.com/
Shareholders
FAQs
What is the current price of Imunon Inc (IMNN)?
The current price of Imunon Inc (IMNN) is 1.59.
What is the symbol of Imunon Inc?
The ticker symbol of Imunon Inc is IMNN.
What is the 52-week high of Imunon Inc?
The 52-week high of Imunon Inc is 41.22.
What is the 52-week low of Imunon Inc?
The 52-week low of Imunon Inc is 2.08.
What is the market capitalization of Imunon Inc?
The market capitalization of Imunon Inc is 6.24M.
Is Imunon Inc (IMNN) currently rated as Buy, Hold, or Sell?
According to analysts, Imunon Inc (IMNN) has an overall rating of Buy, with a price target of 17.00.
What is the Earnings Per Share (EPS TTM) of Imunon Inc (IMNN)?
The Earnings Per Share (EPS TTM) of Imunon Inc (IMNN) is -6.83.
